Sean Murphy, MD
Critical Care Medicine · Winston Salem, NCNPI 1922081223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 348 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 348 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$875
- Boehringer Ingelheim$600
- United Therapeutics Corporation$493
- Regeneron Healthcare Solutions, Inc.$324
- Grifols USA, LLC$318
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,35598%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$102
How this compares
$6,467 in reported general payments places this provider in the 85th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 337 | $255,642 |
| OfevNintedanib Esylate | 18 | $230,676 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 159 | $114,329 |
| Fasenra PenBenralizumab | 17 | $100,754 |
| Breo ElliptaFluticasone/Vilanterol | 147 | $63,115 |
| Spiriva RespimatTiotropium Bromide | 61 | $42,175 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $33,662 |
| SymbicortBudesonide/Formoterol Fumarate | 81 | $28,600 |
| Arnuity ElliptaFluticasone Furoate | 69 | $15,408 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $14,548 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $11,305 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $7,265 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 276 | $6,795 |
| Wixela InhubFluticasone Propion/Salmeterol | 56 | $6,249 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $6,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $1,078 | $360,019613 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $600 | $306,514145 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $875 | $146,894252 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $16 | $7,26520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Winston Salem
- Ashish KhannaWinston Salem$364K
- Hassan YousafWinston Salem$97K
- Farhan AhmedWinston Salem$17K
- Benjamin BregmanWinston Salem$11K
- Jason ThomasonWinston Salem$7K
- David DefeoWinston Salem$6K
- Romel GobunsuyWinston Salem$2K
- Philip KeithWinston Salem$2K
- Blair BrownWinston Salem$2K
- Gregory RossWinston Salem$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.